Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77,143,980
-
Total 13F shares
-
31,854,383
-
Share change
-
+31,854,383
-
Total reported value
-
$1,111,189,598
-
Price per share
-
$34.91
-
Number of holders
-
64
-
Value change
-
+$1,111,189,708
-
Number of buys
-
64
Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2020
As of 30 Sep 2020,
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,854,383 shares.
The largest 10 holders included
Svennilson Peter, TRV GP III, LLC, WELLINGTON MANAGEMENT GROUP LLP, Redmile Group, LLC, Foresite Capital Management IV, LLC, BAKER BROS. ADVISORS LP, BOXER CAPITAL, LLC, Bain Capital Life Sciences Investors, LLC, EcoR1 Capital, LLC, and BlackRock Inc..
This page lists
64
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.